Get the latest news, insights, and market updates on FATE (Fate Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Jul 15, 2025 - $FATE
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data
Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have reaffirmed their Neutral rating on Fate Therapeutics, Inc. (NASDAQ:FATE), while maintaining their price target of $5.00, implying an upside potential of around 358%. This was after the company presented its T819 data on lupus at […] Jul 15, 2025 - $FATE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple